Detailed Narrative
Robust Q1 FY27 Financial Performance
Laurus Labs delivered its highest quarterly revenue of ₹2,026 crores, marking a 29% year-on-year growth. This strong top-line performance was accompanied by significant margin expansion, with EBITDA margins increasing by 7 percentage points over the previous quarter to 31.8%, and gross margins maintained at 62.7%. The company also reported a PAT of ₹368 crores and an improved ROCE of 19% compared to 17.7% in the prior year.
Accelerated CDMO Segment Growth
The CDMO segment demonstrated significant acceleration, reporting sales of ₹835 crores in Q1 FY27, a 69% growth. This was primarily driven by increased contribution from late-stage clinical and commercial deliveries for multiple global partners. Management emphasized the well-diversified nature of the CDMO business, with no single product or customer contributing disproportionately, and 55% of small molecule CDMO revenue coming from commercial supplies.
Steady Momentum in Affordable Medicine
The Affordable Medicine division delivered a strong performance with revenue reaching ₹1,156 crores, an increase of 10% year-on-year. This growth was attributed to higher volumes across established portfolios, including ARVs and onco, where Laurus Labs maintains market leadership. The company continued its regulatory efforts, filing 2 formulation dossiers in developed markets during Q1, bringing the cumulative total to 96, and accelerating product registrations across 3 emerging markets.
Strategic Investments and Capacity Expansion
Laurus Labs continues its aggressive investment strategy, with a Q1 capex of ₹394 crores. The FY27 capex guidance has been revised upwards to ₹2,000 crores, driven by customer demand and the need for capacity in existing programs and new modalities. Key projects include the Phase 1 of Laurus Bio's fermentation facility (400+ kiloliters) expected to be operational by year-end, and the Krka JV's oncology facility ready early next year, followed by a solid oral facility in H2 2027.
Focus on R&D and New Modalities
The company's R&D spend was 5.8% of revenue, a 70% increase year-on-year, reflecting investments in capability development for gene therapy ADC technology infrastructure and complex pipeline building. Laurus Labs also signed a development and commercial agreement with Aarvik Therapeutics for 2 ADC molecules, which are currently in the preclinical stage and expected to generate revenue in 3-4 years. Peptides are also identified as a meaningful growth area, with multiple classes of programs under development.
Long-term Vision and Capital Allocation
Management reiterated its commitment to a transformation strategy, aiming for CDMO to contribute at least 50% of total revenue by FY30. The capital allocation prioritizes high-value business segments to drive near and long-term growth. While ROCE may take time to reach 23% due to heavy capex, it is expected to continue growing from the current 19%. The company's net debt stood at ₹2,656 crores, with a debt-to-EBITDA ratio of 1.28, a slight increase due to capex.